Nitto Avecia Announces Multiple Oligonucleotide Expansions
News Nov 17, 2016
Nitto Avecia Inc has released its progress in expanding the company’s analytical development and oligonucleotide manufacturing capacities. The announcement signals the continuation of Avecia’s robust growth strategy to significantly increase its oligonucleotide drug substance manufacturing capacity in Milford, MA along with the addition of drug product capacity in Irvine, CA and analytical development capabilities in Irvine, CA and Marlboro, MA.
Avecia, a recognized leader in therapeutic nucleic acid manufacturing, is in advanced stages to build a new oligonucleotide drug substance manufacturing facility with additional capacity of more than 1.5mol. Earlier this year, a new 300mmol synthesizer was successfully taken into operation increasing the operational capabilities of its midscale asset. It is expected that in 2017 Avecia’s Milford site will have nearly 3 mol oligonucleotide cGMP synthesis manufacturing capacity operational including aligned downstream assets making it the largest cGMP oligonucleotide facility in the world.
According to Avecia’s president Detlef Rethage, the 300mmol expansion in 2016 followed by the new >1.5mol facility in 2017 will help clients to receive timely oligonucleotide drug substance to advance programs in clinical trials as planned. “Avecia takes pride that the experience and
innovation found within Avecia allows us to bring the new manufacturing units online in a matter of months rather than years,” said Rethage. Analytical development laboratory and office personal now staff a new 6,500 square foot facility in Marlboro, MA.
The Marlboro facility was complemented by Nitto Avecia Pharma Services, a new company created as a result of Avecia’s recent acquisition of Irvine Pharmaceutical Services (Irvine) and Avrio Biopharmaceuticals (Avrio). Nitto Avecia Pharma Services located in Irvine, CA significantly increased Avecia’s analytical capabilities and support of drug product manufacturing.
Rethage said, “Nitto Avecia Pharma Services is the perfect complement to our oligonucleotide drug substance services and a key step in our strategic growth plans. Avecia Group now offers manufacturing and development services on the East Coast, West Coast and in the Midwest at our Cincinnati facility.” As part of its planned growth, Avecia anticipates it will add many additional full-time jobs over the next three months. The new positions will specialize in microbiology, analytical chemistry, manufacturing, quality assurance and engineering.
Source: Story from Nitto Avecia Inc. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks' style and length guidelines.
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
Safety and Efficacy of MERS Treatment Confirmed in Phase I TrialNews
An experimental treatment developed from cattle plasma for Middle East respiratory syndrome (MERS) coronavirus infection shows broad potential, according to a small clinical trial. The treatment, SAB-301, was safe and well tolerated by healthy volunteers, with only minor reactions documented.READ MORE
Alzheimer’s Drug Discovery Foundation Announces $1.8M in New FundingNews
The Alzheimer’s Drug Discovery Foundation (ADDF) announces nearly $1.8 million in new funding, which reflects a commitment to advancing drugs in or near human clinical trials. All five funded programs are potential treatments for Alzheimer’s disease and other forms of dementia.READ MORE